CN112566907A

CN112566907A - Pyrazole derivatives as RET inhibitors

Info

Publication number: CN112566907A
Application number: CN201980053423.0A
Authority: CN
Inventors: 陈正霞; 张杨; 戴美碧; 李婕; 龚珍; 黎健; 陈曙辉
Original assignee: Medshine Discovery Inc
Current assignee: Medshine Discovery Inc
Priority date: 2018-08-17
Filing date: 2019-08-16
Publication date: 2021-03-26
Also published as: WO2020035065A1

Abstract

A series of compounds with pyrazole structures and application thereof in preparing RET kinase inhibitors. The compound is specifically a derivative compound shown as a formula (III), an isomer thereof or a pharmaceutically acceptable salt thereof.

Description

Pyrazole derivatives as RET inhibitors

Reference to related applications

The following priority is claimed in the present application:

CN201810947337.1, App. No. 2018-08-17;

CN201811322012.0, application date 2018-11-07;

CN201811501055.5, application date 2018-12-07;

cn201910482535.x, application No. 2019-06-04;

CN201910487945.3, application date 2019-06-05.

Technical Field

The invention relates to a pyrazole derivative and application thereof in preparing a medicament for treating diseases related to RET kinase inhibitors. In particular to a compound shown as a formula (III) and pharmaceutically acceptable salts thereof.

Background

The RET protein is a receptor tyrosine kinase RTK and is also a transmembrane glycoprotein, expressed by the proto-oncogene RET (rearranged reduced transfection) located on chromosome 10, plays an important role in the development of the renal and enteric nervous systems during the embryonic stage, and is also critical in various tissue homeostasis, such as neurons, neuroendocrine, hematopoietic tissues and male germ cells. Unlike other RTKs, RET does not bind directly to the ligand molecule: such as neurotropic hormone (artemin), glial cell line-derived neurotrophic factor (GDNF), neurturin and persephin, which are ligands belonging to the GNDF Family (GFLs). These ligand GFLs generally bind to GDNF family receptor alpha (GFR alpha), and the resulting GFLs-GFR alpha complex mediates the auto-dimerization of RET proteins, causing a trans autophosphorylation reaction of tyrosine on the intracellular domain, recruitment of related adaptor proteins, activation of a cascade of signaling such as cell proliferation, and related signaling pathways including MAPK, PI3K, JAK-STAT, PKA, PKC, and the like.

There are two major oncogenic activation mechanisms of RET: one is that chromosomal rearrangements produce new fusion proteins, usually a fusion of the kinase domain of RET and a protein comprising a self-dimerization domain; secondly, the RET mutation directly or indirectly activates the kinase activity of RET. These alterations at the somatic or germ cell level are involved in the pathogenesis of a variety of cancers. RET chromosomal rearrangements are present in 5% -10% of papillary thyroid carcinoma patients; 60 percent of medullary thyroid medullary carcinoma has RET point mutation; among all NSCLC patients, there is probably 1-2% with RET fusion proteins, with KIF5B-RET being the most common.

In summary, aberrant RET expression or activation is found in a variety of tumors and gastrointestinal disorders such as irritable bowel syndrome. RET inhibitors are therefore of potential clinical value in neoplastic or bowel disorder diseases.

Disclosure of Invention

The invention provides a compound shown in a formula (III), an isomer thereof or a pharmaceutically acceptable salt thereof,

wherein the content of the first and second substances,

a ring is selected from

The above-mentioned

Optionally substituted by 1,2 or 3R_gSubstitution;

R ₁selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl radical, C_1-3Alkoxy and C_3-6Cycloalkyl radical, said C_1-3Alkyl radical, C_1-3Alkoxy and C_3-6Cycloalkyl is optionally substituted by 1,2 or 3R_aSubstitution;

R ₂selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl and C_1-3Alkoxy radical, said C_1-3Alkyl and C_1-3Alkoxy is optionally substituted by 1,2 or 3R_bSubstitution;

R ₄selected from H, F, Cl、Br、I、OH、NH ₂、CN、C _1-5Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and a 5-6 membered heteroaromatic ring, said C_1- ₅Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and 5-6 membered heteroaromatic rings optionally substituted with 1,2 or 3R_dSubstitution;

R _aand R_bEach independently selected from F, Cl, Br, I, OH and NH₂；

R _dSelected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl radical, C_1-3Alkoxy and C_1-4An alkylamino group;

T ₁、T ₂、T ₃and T₅Each independently selected from CH and N;

T ₄selected from the group consisting of CR₅And N;

L ₂selected from NH and O;

L ₃is selected from-CH (R)₆)-、-CH(R ₆)CH ₂-、-CHCH ₂CH ₂-、-CH(R ₆)-O-、-CHCH ₂-O-、-CH ₂-N(R ₆)-、-CH ₂CH ₂-N(R ₆)-；

R ₅Is selected from H;

R ₆is selected from H and CH₃；

Or R₅、R ₆Are connected together to form a structural unit

Is selected from

R _gSelected from H, F, Cl, Br, I, OH, NH₂And CN;

the 5-to 6-membered heteroaryl group comprises 1,2,3 or 4 heteroatoms or groups of heteroatoms independently selected from-NH-, -O-, -S-and N, respectively.

The invention also provides a compound shown in the formula (II), an isomer thereof or a pharmaceutically acceptable salt thereof,

wherein the content of the first and second substances,

R ₁selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl and C_1-3Alkoxy radical, said C_1-3Alkyl and C_1-3Alkoxy is optionally substituted by 1,2 or 3R_aSubstitution;

R ₃selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl and C_1-3Alkoxy radical, said C_1-3Alkyl and C_1-3Alkoxy is optionally substituted by 1,2 or 3R_cSubstitution;

with "-" carbon atoms as chiral carbon atoms, in the form of (R) or (S) single enantiomers or enriched in one enantiomer;

R ₄selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-5Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and a 5-6 membered heteroaromatic ring, said C_1- ₅Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and 5-6 membered heteroaromatic ringsIs selected from 1,2 or 3R_dSubstitution;

R _a、R _band R_cEach independently selected from F, Cl, Br, I, OH and NH₂；

T ₁、T ₂、T ₃、T ₄and T₅Each independently selected from CH and N;

a ring is selected from

The above-mentioned

Optionally substituted by 1,2 or 3R_gSubstitution;

L ₁and L₂Each independently selected from NH and O;

R _gselected from H, F, Cl, Br, I, OH, NH₂And CN;

The invention also provides a compound shown in the formula (I) or a pharmaceutically acceptable salt thereof,

wherein the content of the first and second substances,

R ₄selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-5Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and a 5-6 membered heteroaromatic ring, said C_1- ₅Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and 5-6 membered heteroaromatic rings optionally substituted with 1,2 or 3R_dSubstitution;

T ₁、T ₂、T ₃、T ₄and T₅Each independently selected from CH and N;

a ring is selected from

The above-mentioned

Optionally substituted by 1,2 or 3R_gSubstitution;

R _gselected from H, F, Cl, Br, I, OH, NH₂And CN;

In some embodiments of the invention, R is₁Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂CH ₃、

The CH₃、CH ₂CH ₃、

Optionally substituted by 1,2 or 3R_aAnd (4) substitution.

In some embodiments of the invention, R is₁Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂CH ₃And

the CH₃、CH ₂CH ₃And

optionally substituted by 1,2 or 3R_aAnd the other variables are as defined herein.

In some embodiments of the invention, R is₁Selected from H, F, Cl、Br、I、OH、NH ₂、CN、CH ₃、CH ₂F、CHF ₂、CF ₃、CH ₂CH ₃And

other variables are as defined herein.

In some embodiments of the invention, R is₁Is selected from CH₃And

other variables are as defined herein.

In some embodiments of the invention, R is₁Is selected from CH₃The other variables are as defined herein.

In some embodiments of the invention, R is₂Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂CH ₃And

the CH₃、CH ₂CH ₃And

optionally substituted by 1,2 or 3R_bAnd the other variables are as defined herein.

In some embodiments of the invention, R is₂Is selected from CH₃The other variables are as defined herein.

In some embodiments of the invention, R is₃Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂CH ₃And

the CH₃、CH ₂CH ₃And

optionally substituted by 1,2 or 3R_cAnd the other variables are as defined herein.

In some embodiments of the invention, R is₃Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂F、CHF ₂、CF ₃、CH ₂CH ₃And

other variables are as defined herein.

In some embodiments of the invention, R is₃Is selected from CH₃The other variables are as defined herein.

In some embodiments of the invention, R is_dSelected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃And

other variables are as defined herein.

In some embodiments of the invention, R is₄Selected from: H. f, Cl, Br, I, OH, NH₂、CN、CH ₃Pyrazolyl, isoxazolyl, imidazolyl, triazolyl, oxazolyl,

The CH₃Pyrazolyl, isoxazolylImidazolyl, triazolyl, oxazolyl,

Optionally substituted by 1,2 or 3R_dAnd the other variables are as defined herein.

In some embodiments of the invention, R is₄Selected from:

other variables are as defined herein.

In some embodiments of the invention, the structural unit

Is selected from

Other variables are as defined herein.

In some embodiments of the invention, the A ring is selected from

Other variables are as defined herein.

In some embodiments of the invention, the A ring is selected from

OthersThe variables are as defined herein.

In some embodiments of the invention, the structural unit

Is selected from

Other variables are as defined herein.

In some embodiments of the invention, the structural unit

Is selected from

Other variables are as defined herein.

In some embodiments of the invention, the structural unit

Is selected from

Other variables are as defined herein.

In some embodiments of the invention, the compound, isomer thereof or pharmaceutically acceptable salt thereof is selected from

Wherein R is₁、R ₂、R ₃、R ₄、L ₂、L ₃、T ₁、T ₂、T ₃、T ₄And T₅As defined herein.

Further aspects of the invention are derived from any combination of the above variables.

The present invention provides a compound represented by the following formula, an isomer thereof, or a pharmaceutically acceptable salt thereof, selected from:

in some embodiments of the invention, the compound, isomer thereof, or pharmaceutically acceptable salt thereof, is selected from the group consisting of:

the invention also provides a pharmaceutical composition which contains the compound, the isomer or the pharmaceutically acceptable salt thereof with effective treatment amount as an active ingredient and a pharmaceutically acceptable carrier.

The invention also provides application of the compound, the isomer or the pharmaceutically acceptable salt thereof in preparing RET kinase inhibitors.

The invention also provides application of the composition in preparing RET kinase inhibitors.

Definitions and explanations

As used herein, the following terms and phrases are intended to have the following meanings, unless otherwise indicated. A particular term or phrase, unless specifically defined, should not be considered as indefinite or unclear, but rather construed according to ordinary meaning. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.

The term "pharmaceutically acceptable" as used herein is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The term "pharmaceutically acceptable salts" refers to salts of the compounds of the present invention, prepared from the compounds of the present invention found to have particular substituents, with relatively nontoxic acids or bases. When compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of a base in neat solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amines or magnesium salts or similar salts. When compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like; and salts of organic acids including acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-toluenesulfonic, citric, tartaric, methanesulfonic, and the like; also included are salts of amino acids such as arginine and the like, and salts of organic acids such as glucuronic acid and the like. Certain specific compounds of the invention contain both basic and acidic functionalities and can thus be converted to any base or acid addition salt.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, which contains an acid or base, by conventional chemical methods. In general, such salts are prepared by the following method: prepared by reacting these compounds in free acid or base form with a stoichiometric amount of the appropriate base or acid, in water or an organic solvent or a mixture of the two.

The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereomers, (D) -isomers, (L) -isomers, as well as racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.

Unless otherwise indicated, the terms "enantiomer" or "optical isomer" refer to stereoisomers that are mirror images of each other.

Unless otherwise indicated, the term "cis-trans isomer" or "geometric isomer" results from the inability of a double bond or a single bond to rotate freely within a ring-forming carbon atom.

Unless otherwise indicated, the term "diastereomer" refers to a stereoisomer in which the molecules have two or more chiral centers and a non-mirror image relationship between the molecules.

Unless otherwise indicated, "(D)" or "(+)" means dextrorotation, "(L)" or "(-) -means levorotation," (DL) "or" (±) "means racemization.

Using solid wedge keys, unless otherwise indicated

And wedge dotted bond

Showing the absolute configuration of a solid centre, by means of straight solid keys

And straight dotted line bond

Showing the relative configuration of the centres of solids, by wavy lines

Representing solid-line keys of wedge shape

Or wedge dotted bond

Or by wavy lines

Indicating straight solid-line keys

And straight dotted line bond

The compounds of the invention may be present specifically. Unless otherwise indicated, the term "tautomer" or "tautomeric form" means that at room temperature, the isomers of different functional groups are in dynamic equilibrium and can be rapidly interconverted. If tautomers are possible (e.g., in solution), then the chemical equilibrium of the tautomers can be reached. For example, proton tautomers (prototropic tautomers), also known as proton transfer tautomers (prototropic tautomers), include interconversions by proton transfer, such as keto-enol isomerization and imine-enamine isomerization. Valence isomers (valencetatomer) include interconversion by recombination of some of the bonding electrons. A specific example of where keto-enol tautomerism is the interconversion between two tautomers of pentane-2, 4-dione and 4-hydroxypent-3-en-2-one.

Unless otherwise indicated, the terms "enriched in one isomer", "isomer enriched", "enantiomer enriched" or "enantiomeric enrichment" refer to a content of one isomer or enantiomer of less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.

Unless otherwise indicated, the term "isomeric excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or enantiomers. For example, if the content of one isomer or enantiomer is 90%, and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80%.

Optically active (R) -and (S) -isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one of the enantiomers of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and the pure enantiomers are recovered. Furthermore, separation of enantiomers and diastereomers is typically accomplished by using chromatography employing a chiral stationary phase, optionally in combination with chemical derivatization (e.g., carbamate formation from amines).

The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be labelled with radioactive isotopes, such as tritium (A), (B), (C³H) Iodine-125 (¹²⁵I) Or C-14(¹⁴C) In that respect For example, deuterium can be used to replace hydrogen to form deuterium-substituted drug, which has stronger bond than common hydrogen and carbon, and has reduced adverse side effect, increased stability and enhanced therapeutic effect compared with non-deuterated drugAnd the biological half-life period of the medicine is prolonged. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

"optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent, and may include variations of deuterium and hydrogen, so long as the valency of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., ═ O), it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on aromatic groups. The term "optionally substituted" means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemical realizability.

When any variable (e.g., R) occurs more than one time in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2R, the group may optionally be substituted with up to two R, and there are separate options for R in each case. Furthermore, combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.

When the number of one linking group is 0, e.g. - (CRR)₀-, represents that the linking group is a single bond.

When one of the variables is selected from a single bond, it means that the two groups to which it is attached are directly connected, for example, where L represents a single bond in A-L-Z means that the structure is actually A-Z.

When a substituent is absent, it indicates that the substituent is absent, e.g., when X is absent in A-X, it indicates that the structure is actually A. When the listed linking groups do not indicate their direction of attachment, the direction of attachment is arbitrary, for example,

wherein the linking group L is-M-W-, in which case-M-W-can be formed by connecting the ring A and the ring B in the same direction as the reading sequence from left to right

The ring A and the ring B may be connected in the reverse direction of the reading sequence from left to right

Combinations of the linking groups, substituents, and/or variants thereof are permissible only if such combinations result in stable compounds.

Unless otherwise specified, the term "C_1-5Alkyl "is intended to mean a straight or branched saturated hydrocarbon group consisting of 1 to 5 carbon atoms. Said C is_1-5The alkyl group comprising C_1-4、C _1-3、C _1-2、C _2-5、C _2-4And C₅Alkyl, etc.; it may be monovalent (e.g., methyl), divalent (e.g., methylene), or multivalent (e.g., methine). C_1-5Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, s-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), and the like.

Unless otherwise specified, the term "C_1-3Alkyl "is intended to mean a straight or branched saturated hydrocarbon group consisting of 1 to 3 carbon atoms. Said C is_1-3The alkyl group comprising C_1-2And C_2-3Alkyl, etc.; it may be monovalent (e.g., methyl), divalent (e.g., methylene), or multivalent (e.g., methine). C_1- ₃Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like. Unless otherwise specified, "C" is_2-8Alkenyl "is intended to mean a straight-chain or branched hydrocarbon group consisting of 2 to 8 carbon atoms containing at least one carbon-carbon double bond, which may be located anywhere in the group. Said C is_2-8Alkenyl radicals comprising C_2-6、C _2-4、C _2-3、C ₄、C ₃And C₂Alkenyl and the like; it may be monovalent, divalent or polyvalent. C_2-8Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, piperylene, hexadienyl, and the like.

Unless otherwise specified, the term "C_1-5Alkoxy "denotes those alkyl groups containing 1 to 5 carbon atoms which are attached to the rest of the molecule through an oxygen atom. Said C is_1-5Alkoxy radicals comprising C_1-5、C _1-4、C _1-3、C _1-2、C _2-5、C _2-4、C ₅、C ₄、C ₃And C₂Alkoxy, and the like. C_1- ₅Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentyloxy (including n-pentyloxy, isopentyloxy and neopentyloxy), and the like.

Unless otherwise specified, the term "C_1-3Alkoxy "denotes those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule through an oxygen atom. Said C is_1-3Alkoxy radicals comprising C_1-2、C _2-3、C ₃And C₂Alkoxy, and the like. C_1-3Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

Unless otherwise specified, the term "C_1-5Alkylamino "refers to those alkyl groups containing from 1 to 5 carbon atoms that are attached to the rest of the molecule through an amino group. Said C is _1-6Alkylamino radicals comprising C_1-5、C _1-4、C _1-3、C _1-2、C _2-5、C _2-4、C ₅、C ₄、C ₃And C₂Alkylamino, and the like. C_1-5Examples of alkylamino include, but are not limited to, -NHCH₃、-N(CH ₃) ₂、-NHCH ₂CH ₃、-N(CH ₃)CH ₂CH ₃、-N(CH ₂CH ₃)(CH ₂CH ₃)、-NHCH ₂CH ₂CH ₃、-NHCH ₂(CH ₃) ₂、-NHCH ₂CH ₂CH ₂CH ₃And the like.

Unless otherwise specified, the term "C_1-4Alkylamino "refers to those alkyl groups containing from 1 to 4 carbon atoms that are attached to the rest of the molecule through an amino group. Said C is_1-4Alkylamino radicals comprising C_1-3、C _1-2、C _2-4、C ₄、C ₃And C₂Alkylamino, and the like. C_1-4Examples of alkylamino include, but are not limited to, -NHCH₃、-N(CH ₃) ₂、-NHCH ₂CH ₃、-N(CH ₃)CH ₂CH ₃、-N(CH ₂CH ₃)(CH ₂CH ₃)、-NHCH ₂CH ₂CH ₃、-NHCH ₂(CH ₃) ₂、-NHCH ₂CH ₂CH ₂CH ₃And the like.

Unless otherwise specified, "C" is_3-6Cycloalkyl "denotes a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, being a monocyclic and bicyclic ring system, said C_3-6Cycloalkyl radicals including C_3-5、C _4-5And C_5-6Cycloalkyl groups and the like; it may be monovalent, divalent or polyvalent. C_3-6Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

Unless otherwise specified, the terms "5-6 membered heteroaromatic ring" and "5-6 membered heteroaryl" are used interchangeably herein, and the term "5-6 membered heteroaryl" denotes a monocyclic group consisting of 5 to 6 ring atoms with a conjugated pi-electron system, of which 1,2,3 or 4 ring atoms are heteroatoms independently selected from O, S and N, the remainder being carbon atoms. Wherein the nitrogen atoms are optionally quaternized and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S (O))_pAnd p is 1 or 2). The 5-6 membered heteroaryl group may be attached to the rest of the molecule through a heteroatom or a carbon atom. The 5-6 membered heteroaryl group includes 5-and 6-membered heteroaryl groups. Examples of such 5-6 membered heteroaryl groups include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, and the like), pyrazolyl (including 2-pyrazolyl, 3-pyrazolyl, and the like), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, and the like), oxazolyl (including 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, and the like), triazolyl (1H-1,2, 3-triazolyl, 2H-1,2, 3-triazolyl, 1H-1,2, 4-triazolyl, and 4H-1,2, 4-triazolyl, and the like), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl, and 5-isoxazolyl, and the like), Thiazolyl (including 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, and the like), furyl (including 2-furyl, 3-furyl, and the like), thienyl (including 2-thienyl, 3-thienyl, and the like), pyridyl (including 2-pyridyl, 3-pyridyl, 4-pyridyl, and the like), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl, 4-pyrimidinyl, and the like).

Unless otherwise specified, C_n-n+mOr C_n-C _n+mIncluding any one particular case of n to n + m carbons, e.g. C_1-12Comprising C₁、C ₂、C ₃、C ₄、C ₅、C ₆、C ₇、C ₈、C ₉、C ₁₀、C ₁₁And C₁₂Also, any one of n to n + m is includedRanges, e.g. C_1-12Comprising C_1- ₃、C _1-6、C _1-9、C _3-6、C _3-9、C _3-12、C _6-9、C _6-12And C_9-12Etc.; similarly, n to n + m means the number of atoms on the ring is n to n + m, for example, the 3-12 membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, a 11-membered ring, and a 12-membered ring, and any range of n to n + m is also included, for example, the 3-12 membered ring includes a 3-6-membered ring, a 3-9-membered ring, a 5-6-membered ring, a 5-7-membered ring, a 6-8-membered ring, and a 6-.

Unless otherwise specified, the term "halogen" or "halogen" by itself or as part of another substituent means a fluorine, chlorine, bromine or iodine atom. Furthermore, the term "haloalkyl" is intended to include monohaloalkyl and polyhaloalkyl. For example, the term "halo (C)₁-C ₄) Alkyl "is intended to include, but not be limited to, trifluoromethyl, 2, 2, 2-trifluoroethyl, 4-chlorobutyl, and 3-bromopropyl, and the like. Unless otherwise specified, examples of haloalkyl include, but are not limited to: trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.

The term "leaving group" refers to a functional group or atom that can be substituted by another functional group or atom through a substitution reaction (e.g., an affinity substitution reaction). For example, representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate groups such as methanesulfonate, toluenesulfonate, p-bromobenzenesulfonate, p-toluenesulfonate and the like; acyloxy groups such as acetoxy, trifluoroacetyloxy, and the like.

The term "protecting group" includes, but is not limited to, "amino protecting group," hydroxyl protecting group, "or" thiol protecting group. The term "amino protecting group" refers to a protecting group suitable for use in preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to: a formyl group; acyl, for example alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups such as benzyl (Bn), trityl (Tr), 1-bis- (4' -methoxyphenyl) methyl; silyl groups, such as Trimethylsilyl (TMS) and t-butyldimethylsilyl (TBS), and the like. The term "hydroxy protecting group" refers to a protecting group suitable for use in preventing side reactions of a hydroxy group. Representative hydroxy protecting groups include, but are not limited to: alkyl groups such as methyl, ethyl and tert-butyl; acyl groups, such as alkanoyl (e.g., acetyl); arylmethyl groups such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (benzhydryl, DPM); silyl groups, such as Trimethylsilyl (TMS) and t-butyldimethylsilyl (TBS), and the like.

The compounds of the present invention may be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combinations thereof with other chemical synthetic methods, and equivalents thereof known to those skilled in the art, with preferred embodiments including, but not limited to, examples of the present invention.

The compounds of the present invention may have a variety of uses or indications, including but not limited to the specific uses or indications enumerated herein.

The solvent used in the present invention can be commercially available. The invention employs the following abbreviations: aq represents water; HATU represents O- (7-azabenzotriazol-1-yl) -N, N' -tetramethyluronium hexafluorophosphate; EDC stands for N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride; m-CPBA represents 3-chloroperoxybenzoic acid; eq represents equivalent, equivalent; m represents mol/L; CDI represents carbonyldiimidazole; DCM represents dichloromethane; PE represents petroleum ether; DIAD represents diisopropyl azodicarboxylate; DMF represents N, N-dimethylformamide; DMSO represents dimethyl sulfoxide; EtOAc for ethyl acetate; EtOH stands for ethanol; MeOH represents methanol; CBz represents benzyloxycarbonyl, an amine protecting group; BOC represents tert-butoxycarbonyl as an amine protecting group; HOAc represents acetic acid; n acetonitrile BH₃Represents sodium cyanoborohydride; r.t. represents room temperature; O/N stands for overnight; THF represents tetrahydrofuran; boc₂O represents di-tert-butyl dicarbonateAn ester; trifluoroacetic acid represents trifluoroacetic acid; DIPEA stands for diisopropylethylamine; SOCl₂Represents thionyl chloride; CS₂Represents carbon disulfide; TsOH represents p-toluenesulfonic acid; NFSI represents N-fluoro-N- (phenylsulfonyl) benzenesulfonamide; NCS represents 1-chloropyrrolidine-2, 5-dione; n-Bu₄NF represents tetrabutyl ammonium fluoride; iPrOH represents 2-propanol; mp represents melting point; LDA stands for lithium diisopropylamide.

The compounds are used according to the conventional naming principle in the field

The software names, and the commercial compounds are under the supplier catalog name.

Technical effects

The compound has excellent inhibitor activity on RET and mutant RET V804M thereof, and has excellent treatment effect on patients with RET abnormal tumors.

Detailed Description

The present invention is described in detail below by way of examples, but is not meant to be limited to any of the disadvantages of the present invention. Having described the invention in detail and having disclosed specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

Example 1

Step one

A catalytic amount of DMF (2.32g,31.74mmol) was added to a mixture of 6-chloronicotinic acid (50g,317.35mmol) containing thionyl chloride (150mL) and refluxed at 85 ℃ for 3 hours under nitrogen. The solution was spun off and dissolved in DCM (1200mL), methoxy-N-methyl-amino hydrochloride (46.43g,476.03mmol) was added, cooled to 0 deg.C, triethylamine (96.34g,952.05mmol) was added dropwise, and stirring was carried out at 25 deg.C for 16 hours. Adding saturated sodium bicarbonate solution into the reaction solution, and layering to obtain an organic phase. The organic phase was dried over sodium sulfate and concentrated under reduced pressure to give 1 a.

LCMS(ESI)m/z:200.9[M+1] ⁺

Step two

Methylmagnesium bromide (3M,119.04mL) was added dropwise to a solution of 1a (59.71g,297.60mmol) in THF (500mL) at 0 deg.C and stirred for 2h at 25 deg.C. The reaction mixture was quenched by addition of saturated ammonium chloride (500mL), extracted with EtOAc (500 mL. times.2), the combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was isolated by flash column chromatography on silica gel (PE: EtOAC ═ 3:1) to give 1 b.

Step three

To a solution of 4-fluoro-pyrazole (4.98g,57.85mmol), 1b (9g,57.85mmol) in DMF (80mL) was added potassium carbonate (19.99g,144.62mmol), and the mixture was stirred at 100 ℃ for 16 hours. Water (400mL) was added to the reaction solution, EtOAc (400 mL. times.2) was added thereto for extraction, and the organic phases were combined. The organic phase was washed successively with water (600mL) and saturated aqueous sodium carbonate (600 mL). Finally, the organic phase is dried by anhydrous sodium sulfate and is decompressed and concentrated to obtain a crude product. The crude product was isolated by flash column chromatography on silica gel (PE: EtOAC ═ 3:1) to give 1 c.

LCMS(ESI)m/z:205.9[M+1] ⁺

Step four

To a solution of 1c (1g,4.87mmol) in THF (10mL) was added (R) -tert-butylsulfinamide (590.68mg,4.87mmol), followed by the addition of tetraethyltitanium oxide (2.62g,9.75mmol,2.38mL, 85% purity), stirring at 75 deg.C for 20 hours, cooling to-78 deg.C, and dropwise addition of a solution of lithium tri-sec-butylborohydride (1M,14.62mL) and stirring at-78 deg.C for 30 minutes. The reaction was quenched by addition of MeOH (5mL) to the reaction solution at-78 deg.C, followed by addition of water (20mL) and extraction with EtOAc (20 mL. times.2). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure to give crude product, which was separated by flash silica gel column (DCM: MeOH ═ 10:1) to give 1 d.

LCMS(ESI)m/z:310.9[M+1] ⁺,333.1[M+23] ⁺

Step five

To 1d (8g,25.77mmol) were added MeOH (67.30g,2.10mol,85mL) and hydrogen chloride in dioxane (4M,85mL,13.19eq) and stirred at 30 ℃ for 2 h. The reaction solution is decompressed, concentrated and dried to obtain a crude product, then water is added for dilution, and the pH value is adjusted to 8 by using a saturated sodium carbonate solution. Adding dichloromethane for extraction to obtain an organic phase. The organic phase is decompressed and concentrated to obtain a crude product. The crude product was isolated via flash silica gel column (DCM: MeOH ═ 10:1) to give 1 e. Chiral resolution by HPLC (column: DAICEL CHIRALPAK AD-H (250 mm. times.50 mm,10 μm); mobile phase: [ 0.1% ammonia EtOH ]; B%: 35% -35%, retention time: 5.386 min, main peak 2 was collected) to give 1e (99.85% ee%).

¹H NMR(400MHz,DMSO-d ₆)δ8.66(d,J＝4.02Hz,1H),8.42(d,J＝2.01Hz,1H),7.99(dd,J＝2.01,8.53Hz,1H),7.87-7.91(m,1H),7.84(d,J＝8.53Hz,1H),4.08(q,J＝6.53Hz,1H),1.72-2.34(m,2H),1.29(d,J＝6.53Hz,3H).

Step six

2, 4-dichloro-6-methyl-pyrimidine (10g,61.35mmol), 5-methyl-3-amino-1H-pyrazole (6.55g,67.48mmol), diisopropylethylamine (11.89g,92.02mmol,16.03mL) was added to DMSO (30mL), and the reaction was stirred at 60 ℃ for 16 hours. Cooling the reaction liquid to 20-30 ℃, pouring the reaction liquid into 200mL of ice water, stirring for 1 hour at 15-20 ℃, filtering, and performing reduced pressure spin drying on a filter cake at 40-50 ℃ to obtain 1 f.

LCMS(ESI)m/z:224.0[M+1] ⁺，225.9[M+3] ⁺

¹H NMR(400MHz,DMSO-d ₆)δppm 12.08(s,1H)10.14(s,1H)6.50-7.68(m,1H)5.55-6.45(m,1H)2.25(s,3H)2.20(s,3H).

Step seven

1f (30mg, 134.13. mu. mol), tert-butoxycarbonylpiperidine (44.83mg, 240.69. mu. mol), diisopropylethylamine (69.34mg, 536.52. mu. mol, 93.45. mu.L) was added to N-methylpyrrolidone (2 mL). The reaction was stirred at 90 ℃ for 16 hours, the reaction was cooled to room temperature, 5mL of water was added, followed by extraction with EtOAc (5 mL. times.2), and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1 g.

LCMS(ESI)m/z:374.7[M+1] ⁺,318.2[M-55] ⁺

Step eight

1g (200mg, 535.54. mu. mol) was added to EtOAc (5mL), and a solution of hydrogen chloride in ethyl acetate (4M, 267.77. mu.L) was added dropwise to the reaction mixture, followed by stirring at 20-30 ℃ for 16 hours. And (3) directly carrying out decompression spin-drying on the reaction liquid at 40-50 ℃ for 1 h.

LCMS(ESI)m/z:274.0[M+1] ⁺

¹H NMR(400MHz,DMSO-d6)δppm 11.18(m,1H)9.81(s,2H)6.18-6.43(m,1H)4.21-4.33(m,4H)3.25(m,4H)2.42(s,3H)2.28-2.31(m,1H)2.26(s,3H).

Step nine

Triphosgene (23.95mg, 80.70. mu. mol) was added to DCM (4mL), diisopropylethylamine (62.58mg,

484.19 μmol,84.33 μ L) was added to the reaction solution, 1e (26.63mg,129.12 μmol) was added to the reaction solution with stirring at a reaction temperature of 0 to 5 ℃, the reaction was stirred for 10 minutes at 0 to 5 ℃, then 1h (50mg,161.40 μmol) and diisopropylethylamine (62.58mg,484.19 μmol,84.33 μ L) were added to the reaction solution, and the system was stirred for 1 hour at 0 to 5 ℃. The reaction solution is directly decompressed and concentrated to obtain a crude product. The crude product was separated and purified by preparative chromatography (HCl system) to give the hydrochloride salt of example 1, the hydrochloride salt of example 1 was added to sodium bicarbonate solution, extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 1.

LCMS(ESI)m/z:506.1[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δppm 8.52(d,J＝4.27Hz,1H),8.44(s,1H),7.98-8.06(m,1H),7.89-7.97(m,1H),7.72(d,J＝4.02Hz,1H),6.19-6.65(m,2H),5.00-5.08(m,1H),3.91(m,4H),3.69(m,4H),2.46(s,3H),2.41(s,3H),1.57(d,J＝7.03Hz,3H).

Examples 2 and 3

Step one

Compound 2a (500mg,3.21mmol), dimethylamine hydrochloride (1.81g,16.07mmol) was added to ethanol (5mL) and stirred at 80 ℃ under reflux for 2 hours. And cooling the reaction liquid to 25 ℃, then spin-drying, adding tert-butyl methyl ether for dissolving, washing with 10% citric acid, adjusting the pH to 10-11 with 1mol/L sodium hydroxide, extracting for 3 times with 20mL of tert-butyl methyl ether, collecting the organic phase, drying with anhydrous sodium sulfate, filtering, and spin-drying to obtain 2 b.

LCMS(ESI)m/z:164.8[M+1] ⁺

¹H NMR(400MHz,CDCl ₃)δppm 8.67-8.86(m,1H),7.90-8.11(m,1H),6.36-6.66(m,1H),3.18(s,6H),2.49(s,3H).

Step two

Add 2b (220mg,1.34mmol) to MeOH (10mL) followed by ammonium acetate (1.03g,13.40mmol) and stir at 65 deg.C for 1h, after complete dissolution add sodium cyanoborohydride (252.59mg,4.02mmol) and stir at 65 deg.C overnight. The reaction solution after the reaction of the raw materials is directly spin-dried to obtain a crude product. The crude product was purified by preparative chromatography plate (DCM/MeOH-10/1, Rf-0.2.3) to give 2 c.

LCMS(ESI)m/z:165.8[M+1] ⁺

¹H NMR(400MHz,CDCl ₃)δppm 8.11(d,J＝2.00Hz,1H),7.59(dd,J＝8.80,2.64Hz,1H),6.55(d,J＝9.20Hz,1H),4.27-4.29(m,1H),2.93-3.23(m,16H),1.57(d,J＝6.80Hz,3H).

Step three

2c (57mg, 344.96. mu. mol) DIEA (133.75mg,1.03mmol, 180.25. mu.L, 3eq) and triphosgene (51.18mg, 172.48. mu. mol) were added to DCM (2mL) at 0 ℃ and stirred for 10min, and a mixture of compound 1h (113.15mg, 413.95. mu. mol), DIEA (133.75mg,1.03mmol) and DCM (2mL) at 0 ℃ was added to the above reaction system and reacted at 0 ℃ for 20 min. Directly spin-drying the reaction solution to obtain a crude product. The crude product is subjected to preparative chromatography (column: Xtimate C18150X 25mm X5 μm; mobile phase: water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 10% -30%, 7min), separated and purified, and then subjected to SFC resolution (column: DAICEL CHIRALPAK AS-H (250mm X30 mm,5 μm); mobile phase: 0.1% ammonia EtOH; B%: 45% -45%)

Example 2 (retention time: 4.957min) was obtained.

LCMS(ESI)m/z:465.4[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δppm 8.03(d,J＝2.80Hz,1H),7.55(dd,J＝8.80,2.51Hz,1H),6.65(d,J＝8.80Hz,1H),6.11-6.12(m,2H),3.74-3.78(m,4H),3.48-3.52(m,4H),3.01(s,6H),2.28(s,3H),2.21(s,3H).

Example 3 (retention time: 5.737min) was obtained.

LCMS(ESI)m/z:465.4[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δppm 8.03(d,J＝2.80Hz,1H),7.56(dd,J＝8.80,2.51Hz,1H),6.64(d,J＝8.80Hz,1H),6.11-6.12(m,2H),3.75-3.79(m,4H),3.48-3.51(m,4H),3.04(s,6H),2.28(s,3H),2.21(s,3H).

Example 4

Step one

2, 6-dichloro, 4-methylpyridine (5g,30.86mmol), N-Boc piperazine (6.32g,33.95mmol) and cesium carbonate (30.17g,92.58mmol) were added together to DMF (100mL) and the reaction was stirred in an oil bath heated to 120 ℃ for 16 h. Directly filtering the reaction solution, collecting the filtrate, and directly spin-drying to obtain a crude product. The crude product was purified by flash silica gel column (PE/EtOAc ═ 5/1, Rf ═ 0.5) to give 4 b.

¹H NMR(400MHz,CDCl3)δ6.49(s,1H),6.30(s,1H),3.51(s,8H),2.24(s,3H),1.48(s,9H).

Step two

4b (373.76mg,3.85mmol) was dissolved in 1, 4-dioxane (10mL) and Pd was then added₂(dba) ₃(146.84mg, 160.36. mu. mol), 5-methyl-3-amino-1H-pyrazole (1g,3.21mmol), 2-dicyclohexylphosphonium-2, 4, 6-triisopropylbiphenyl (229.33mg, 481.07. mu. mol) and cesium carbonate (3.13g,9.62mmol) were added together to the reaction solution, heated to 140 ℃ by a microwave synthesizer and reacted for 1 hour with stirring. Directly filtering the reaction solution, collecting the filtrate, and spin-drying to obtain a crude product. Crude product passing through quick siliconPurification on a gel column (PE/EtOAc ═ 1/1, Rf ═ 0.2) afforded product 4 c.

LCMS(ESI)m/z:373.3[M+H] ⁺

Step three

4c (100mg, 268.48. mu. mol) was dissolved in EtOAc (5mL), followed by dropwise addition of HCl/EtOAc (4M,10mL) and finally the reaction was stirred at 20-30 ℃ for 2 h. As the reaction proceeds, the solids in the reaction solution gradually increase. The reaction solution was stirred for further 16 hours. LCMS detection showed disappearance of starting material and the main peak was the product peak. Directly concentrating the reaction solution to dryness to obtain 4 d.

LCMS(ESI)m/z:273.2[M+1] ⁺

Step four

Compound 4d (40mg, 146.87. mu. mol) and N, N-diisopropylethylamine (56.95mg, 440.61. mu. mol, 76.75. mu.L) were added to methylene chloride (5mL) at 0 ℃ followed by the addition of compound 1e (36.35mg, 176.25. mu. mol), N, N-diisopropylethylamine (56.95mg, 440.61. mu. mol) and triphosgene (21.79mg, 73.44. mu. mol) and the reaction was stirred at 25-30 ℃ for 10 minutes. Directly spin-drying the reaction solution at 20-30 ℃ to obtain a crude product. The crude product was sent to a preparative chromatography column (column: Xtimate C18150X 25mm X5 μm; mobile phase: [ water (0.225% trifluoroacetic acid) -acetonitrile ]; B%: 25% -45%, 7 min). The trifluoroacetate salt of example 4 is obtained, the trifluoroacetate salt of example 4 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 4.

LCMS(ESI)m/z:505.3[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δ8.47(br s,2H),7.98～7.90(m,1H),7.84(s,1H),7.69(s,1H),6.34(s,1H),6.23(s,1H),5.83(s,1H),5.02～4.99(m,1H),3.66-3.74(m,8H),2.37(s,3H),2.33(s,3H),1.57(d,J＝6.8Hz,3H).

Examples 6 and 7

Step one

4-pyrazole-1-benzoic acid (7g,37.20mmol) and methoxymethylamide hydrochloride (5.44g,55.80mmol) were dissolved in DMF (110mL), HATU (14.14g,37.20mmol) and DIPEA (24.04g,185.99mmol,32.40mL) were added, and the mixture was stirred at 30 ℃ for 16 hours. LCMS indicated product formation. The reaction mixture was extracted with ethyl acetate (100 ml. times.3) and the combined organic phases were washed with water (100 ml. times.2), saturated sodium chloride solution (100 ml. times.2), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 6 a.

¹H NMR(400MHz,CDCl ₃-d ₆)δ7.95(d,J＝4Hz,1H),7.74-7.81(m,2H),7.58-7.73(m,3H),6.36-6.49(m,1H),3.51(s,3H),3.32(s,3H).

Step two

To a solution of compound 6a (9.4g,40.65mmol) in THF (90mL) was added dropwise methylmagnesium bromide (3M,27.10mL) at 0 deg.C, slowly warmed to 30 deg.C and stirred for 1 hour. The reaction solution was quenched by addition of a saturated ammonium chloride solution, followed by extraction with ethyl acetate (150 ml. times.3), and the organic layers were combined, washed with a saturated sodium chloride solution (200 ml. times.3), dried over anhydrous sodium sulfate, and finally the solvent was removed by rotary removal under reduced pressure to give a crude product. And (3) performing silica gel column chromatography (PE: EA is 3:1, and Rf is 0.57), finding that a product is easy to separate out, adding a small amount of ethyl acetate into a cross product obtained by column chromatography to dissolve the cross product, adding a large amount of petroleum ether, washing out white solid, and filtering to obtain a product 6 b.

Step three

MeOH (50mL) was added to 6b (4.75g,25.51mmol) to dissolve and add ammonium acetate (19.66g,255.09mmol), stir at 60 ℃ for 1h then add sodium cyanoborohydride (4.81g,76.53mmol), and keep stirring at 60 ℃ for 3 h. TLC monitoring indicated the formation of product. The reaction was dried by spinning to give crude product, which was separated by silica gel column chromatography (DCM: MeOH: 10:1, Rf: 0.22) to give product 6 c.

¹H NMR(400MHz,DMSO-d ₆)δ8.50(d,J＝2.4Hz,1H),7.87(d,J＝8.8Hz,2H),7.75(d,J＝1.6Hz,1H),7.56(d,J＝8.8Hz,2H),6.49-6.62(m,1H),4.36(q,J＝6.8Hz,1H),1,45(d,J＝6.8Hz,3H).

Step four

Compound 1h (72.99mg, 267.04. mu. mol) was dissolved in DCM (1mL) at 0 ℃ and DIEA (103.54mg, 801.11. mu. mol) was added to it, to which was added compound 6c, DIEA (103.54mg, 801.11. mu. mol, 139.54. mu.L), triphosgene (39.62mg, 133.52. mu. mol), and the mixture stirred for 10 min. Stirring at 0 deg.C for 10 min. LCMS indicated product formation. And (4) spin-drying the reaction liquid to obtain a crude product. The crude product was separated using a preparative column (column: XTTIMATE C18150X 25mm X5 μm; mobile phase: water (0.075% trifluoroacetic acid) -acetonitrile; B%: 15% -35%, 8min) to give 6 d.

LCMS(ESI)m/z:487.2[M+1] ⁺

Step five

Subjecting compound 6d (28mg,57.55 μmol) to chiral resolution under SFC resolution conditions of column DAICEL CHIRALPAK AD (250 mm. times.30 mm,10 μm); mobile phase of [ 0.1% ammonia EtOH ]; b%: 55% -55% ]

Peak 1 was collected (retention time: 2.111min), giving example 6.

LCMS(ESI)m/z:487.2[M+1] ⁺

¹H NMR(400MHz,CDCl ₃-d ₆)δ7.88(d,J＝2.4Hz,1H),7.69(s,1H),7.63(d,J＝8.4Hz,2H),7.42(d,J＝8.8Hz,2H),6.43(d,J＝1.6Hz,1H),5.95-6.13(m.2H),5.01-5.10(m,1H),4.85(s,1H),3.74-3.8(m,4H),3.43-3.45(m,4H),2.27(s,3H),2.22(s,4H),1.51(d,J＝7.2Hz,3H).

Peak 2 was collected (retention time: 3.756min) to give example 7.

LCMS(ESI)m/z:487.2[M+1] ⁺

¹H NMR(400MHz,CDCl ₃-d ₆)δ7.89(d,J＝2.4Hz,1H),7.71(d,J＝1.2Hz,1H),7.64(d,J＝8.4Hz,2H),7.43(d,J＝8.4Hz,2H),6.45(t,J＝2Hz,1H),6.11(s,1H),6.01(s,1H),5.03-5.11(m,1H),4.76(d,J＝7.2Hz,1H),3.77-3.86(m,4H),3.43-3.48(m,4H),2.29(s,3H),2.23(s,3H),1.53(d,J＝7.2Hz,3H).

Examples 8 and 9

Step one

Compound 8a (500mg,3.03mmol) and ammonium acetate (2.33g,30.27mmol) were added to methanol (7mL), the reaction was stirred for 1 hour at 65 deg.C, then sodium cyanoborohydride (570.64mg,9.08mmol) was added portionwise to the reaction, and the reaction was stirred for an additional 12 hours at 65 deg.C. The reaction solution was directly spin dried at 40-50 ℃ under reduced pressure to give crude product, which was purified by thin layer chromatography plate (PE/EtOAc ═ 1/1) to give 8 b.

¹H NMR(400MHz,CDCl ₃)δppm 8.19(d,J＝2.51Hz,1H),7.79(dd,J＝8.78,2.51Hz,1H),6.80(s,1H),4.25(q,J＝7.03Hz,2H),3.48(s,3H),1.37(t,J＝7.03Hz,3H).

Step two

Compound 1h (100mg, 365.85. mu. mol) and DIEA (141.85mg,1.10mmol, 191.17. mu.L) were added to a reaction solution containing DCM (2mL) and stirred for 10 min. Adding NN-diisopropylethylamine (141.85mg,1.10mmol,191.17 mu L), 8B (60.81mg,365.85 mu mol) and triphosgene (54.28mg,182.92 mu mol) into a stirred DCM (2mL) solution at 0-5 ℃, stirring for 20min at 0-5 ℃, directly concentrating the reaction solution under reduced pressure to obtain a crude product, and purifying by using a preparative chromatographic column (chromatographic column: XYTIMATE C18150X 25mm X5 mu m; mobile phase of [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 17% -27%, 9min) to obtain 8C.

LCMS(ESI)m/z 466.3[M+1] ⁺

Step three

Compound 8c (28mg, 60.14. mu. mol) was resolved by SFC (column: DAICEL CHIRALPAK IC (250 mm. times.30 mm,10 μm); mobile phase: [ 0.1% aqueous ammonia EtOH ]; B%: 50%).

Peak 1 (retention time 5.211min) was collected to give example 8.

LCMS(ESI)m/z:466.2[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δppm 8.09(d,J＝2.51Hz,1H)7.70(dd,J＝8.78,2.51Hz,1H)6.76(d,J＝8.53Hz,1H)6.13(s,2H)4.07-4.18(m,1H)3.77-3.80(m,4H)3.49-3.53(m,4H)3.49-3.52(m,1H)2.29(s,3H)2.22(s,3H)1.50(d,J＝4.0Hz,3H)1.37-1.40(m,3H).

Peak 2 was collected (retention time 6.498min) to give example 9.

LCMS(ESI)m/z:466.2[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δppm 8.09(d,J＝2.51Hz,1H)7.70(dd,J＝8.78,2.51Hz,1H)6.76(d,J＝8.53Hz,1H)6.13(s,2H)3.78-3.80(m,4H)3.49-3.52(m,4H)2.29(s,3H)2.22(s,3H)1.50(d,J＝4.0Hz,2H)1.48-1.51(m,1H)1.37-1.40(m,3H).

Examples 10 and 11

Step one

Compound 4d (40mg, 146.87. mu. mol) was dissolved in DCM (1mL), DIEA (56.95mg, 440.61. mu. mol, 76.75. mu.L) was added, and stirring was carried out at 0 ℃ for 10 min. To the above reaction solution was added dropwise a solution of compound 6c (27.50mg, 146.87. mu. mol), DIEA (56.95mg, 440.61. mu. mol), triphosgene (21.79mg, 73.44. mu. mol) in DCM (1mL) obtained after stirring at 0 ℃ for 10 minutes. Stirring at 0 deg.C for 10 min. The reaction solution was spin-dried to obtain a crude product, which was purified by preparative chromatography (column: Xtimate C18150X 25mm X5 μm; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 32% -46%, 7min) to obtain product 10 a.

LCMS(ESI)m/z:486.4[M+1] ⁺

Step two

Compound 10a was subjected to chiral resolution. The SFC resolution conditions are that a chromatographic column is YMC CHIRAL Amylose-C (250mm multiplied by 30mm,10 mu m; mobile phase: 0.1% ammonia isopropanol; B%: 50% -50% for min.

Peak 1 was collected (retention time 1.642min) yielding example 10.

LCMS(ESI)m/z:486.4[M+1] ⁺

¹H NMR(400MHz,CDCl ₃)δ7.90(d,J＝2.4Hz,1H),7.71(d,J＝1.6Hz,1H),7.66(d,J＝8.8Hz,2H),7.43(d,J＝8.8Hz,2H),6.52(s,1H),6.45(t,J＝1.6Hz,1H),6.18(s,1H),5.95(s,1H),5.83(s,1H),5.02-5.16(m,1H),4.70(d,J＝6.8Hz,1H),3.47-3.54(m,8H),2.28(s,3H),2.21(s,3H),1.36-1.45(m,3H).

Peak 2 was collected (retention time 2.516min) to give example 11.

LCMS(ESI)m/z:486.4[M+1] ⁺

¹H NMR(400MHz,CDCl ₃)δ7.88(d,J＝2.8Hz,1H),7.70(d,J＝1.2Hz,1H),7.63(d,J＝8.4Hz,2H),7.42(d,J＝8.8Hz,2H),6.75(s,1H),6.43-6.46(m,1H),6.11(s,1H),5.94(s,1H),5.82(s,1H),5.02-5.14(m,1H),3.49-3.52(m,8H),2.26(s,4H),2.20(s,3H),1.36-1.38(m,3H).

Example 12

Step one

Compound 12a (200mg,1.23mmol) and 3-methyl-3-pyrazolin-5-one (144.44mg,1.47mmol) were added to DMSO (2mL), DIEA (237.86mg,1.84mmol, 320.57. mu.L) was added dropwise to the reaction solution, and the reaction was stirred at 60 ℃ for 16 hr. And cooling the reaction liquid to 20-30 ℃, then dropwise adding the reaction liquid into 20mL of ice water, precipitating a light yellow solid, and carrying out vacuum filtration to obtain a compound 12 b.

LCMS(ESI)m/z 224.6[M+1] ⁺

Step two

Compound 12b (100mg, 445.14. mu. mol) and N-BOC piperazine (165.82mg, 890.29. mu. mol) were added to NMP (2mL), DIEA (230.13mg,1.78mmol) was added dropwise to the reaction solution, and the reaction was stirred at 100 ℃ for 1 hr. The reaction solution is cooled to room temperature, then 10mL of water is added, then ethyl acetate (10mL multiplied by 2) is used for extraction, organic phases are combined, the organic phases are dried by anhydrous sodium sulfate and are dried by decompression and spin-drying at 40-50 ℃ to obtain a crude product, and the crude product is purified by column chromatography (PE/EA is 3/1-1/1) to obtain the compound 12 c.

LCMS(ESI)m/z 375.2[M+1] ⁺

Step three

Compound 12c (45mg, 120.18. mu. mol) was added to DCM (4mL), and TFA (2.74g,24.04mmol,1.78mL) was added to the reaction mixture, followed by reaction at 20-30 ℃ for 20 min. And (3) directly carrying out reduced pressure spin drying on the reaction liquid at 40-50 ℃ to obtain the TFA salt of the compound 12 d.

LCMS(ESI)m/z 274.8[M+1]+

Step four

The TFA salt of Compound 12d (50mg, 128.75. mu. mol) was added to DCM (5mL), DIEA (49.92mg, 386.26. mu. mol, 67.28. mu.L) was then added to the reaction mixture, the reaction temperature was lowered to 0 ℃ to determine reaction mixture 1, 1e (23.90mg, 115.88. mu. mol) was added to DCM (5mL), triphosgene (19.10mg, 64.38. mu. mol) was added to the reaction mixture, DIEA (49.92mg, 386.26. mu. mol, 67.28. mu.L) was added dropwise to the reaction mixture, the reaction temperature was lowered to 0 ℃ to determine reaction mixture 2, and reaction mixtures 1 and 2 were each stirred at 0 ℃ for 10min, reaction mixture 1 was slowly added dropwise to reaction mixture 2 at 0 ℃ and the reaction mixture was stirred at 0 ℃ for 10 min. 10mL of water is added into the reaction solution, then DCM (5mL multiplied by 2) is used for extraction, organic phases are combined, the organic phases are dried by anhydrous sodium sulfate and are dried by decompression and spin-drying at 40-45 ℃ to obtain a crude product, and the crude product is purified by a thin-layer chromatography plate to obtain the example 12.

LCMS(ESI)m/z 507.3[M+1] ⁺

¹H NMR(400MHz,DMSO-d ₆)δ12.19(s,1H)8.58-8.76(m,1H)8.41(d,J＝2.01Hz,1H)7.93-7.97(m,1H)7.91(d,J＝4.27Hz,1H)7.85-7.89(m,1H)6.99(d,J＝7.53Hz,1H)6.01(s,1H)5.83(s,1H)4.92(quin,J＝7.03Hz,1H)3.59-3.67(m,4H)3.37-3.42(m,4H)2.23(s,6H)1.43(d,J＝7.03Hz,3H).

Example 13

Step one

Compound 13a TFA salt (0.06g,154.90 μmol) was dissolved in anhydrous methanol (1mL), sodium borohydride (121.25mg,3.21mmol) was added at 0 deg.C, and stirred at 25 deg.C for 2 hr. The reaction mixture was added to water (10mL), extracted with ethyl acetate (10 mL. times.3), the organic phases combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by plate chromatography (petroleum ether: ethyl acetate 1:1) to give example 13b as a white oil.

LCMS(ESI)m/z:190.1[M+1] ⁺

Step two

Compound 13b (0.06g, 154.90. mu. mol, TFA salt) and DIEA (60.06mg, 464.70. mu. mol, 80.94. mu.L) were added to dried dichloromethane (1mL), stirred for 10mins to form solution 1, and triphosgene (137.90mg, 464.70. mu. mol) was added to a solution of compound 1h and DIEA (60.06mg, 464.70. mu. mol, 80.94. mu.L, 3eq) in dichloromethane (1mL) at 0 ℃ to react for 10mins at 0 ℃, and then solution 1 was added dropwise to the reaction solution to react for 20mins at 0 ℃. Water (2mL) was added to the reaction mixture to quench the reaction and concentrated to give the crude product. The crude product was purified by preparative chromatography (column: Boston Green ODS 150X 30mm5 μm; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 29% -45%, 9min) to give the trifluoroacetate salt of example 13, which was added to a sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give example 13.

LCMS(ESI)m/z:475.2[M+1] ⁺

¹H NMR(400MHz,MeOH-d ₄)δ＝8.61(d,J＝2.4Hz,1H),8.49(s,1H),8.07-7.99(m,1H),7.99-7.91(m,1H),7.78(s,1H),6.56(br s,1H),6.44-6.14(m,1H),5.93(q,J＝6.6Hz,1H),3.96-3.49(m,9H),2.40(s,3H),2.34(s,3H),1.67(d,J＝6.4Hz,3H).

Example 14

Step one

2-bromo-5-hydroxypyridine (1g,5.75mmol) was dissolved in acetone (10mL), methyl chloroacetate (748.46mg,6.90mmol,608.50uL) and potassium carbonate (794.31mg,5.75mmol) were added, and the mixture was stirred at 60 ℃ for 16 hours. Filtering to remove insoluble solid, and spin-drying the filtrate to obtain crude product. The crude product was purified by flash column chromatography on silica gel (PE: EA ═ 3:1) to give compound 14a (1.1g,4.47 mmol).

LCMS(ESI)m/z:245.4[M+1] ⁺,247.4[M+3] ⁺

Step two

Compound 14a (50mg,203.20umol) was dissolved in toluene (1mL), and 4-fluoro-1-hydro-pyrazole (14.57mg,169.34umol), cuprous iodide (3.23mg,16.93umol), potassium carbonate (46.81mg,338.67umol), N1, N2-dimethylcyclohexanediamine (4.82mg,33.87umol) were added and stirred at 110 ℃ for 16 hours. Insoluble substances are removed by filtration, and the filtrate is dried by spinning to obtain a crude product. The crude product was purified by preparative chromatography (PE: EA ═ 1:1) to afford compound 14 b.

¹H NMR(400MHz,CDCl ₃)δppm8.31(d,J＝4.4Hz,1H),8.07(d,J＝2.8Hz,1H),7.88(d,J＝8.8Hz,1H),7.55(d,J＝4.4Hz,1H),7.37(dd,J＝8.8,2.8Hz,1H),4.71(s,2H),3.83(s,3H).

Step three

Compound 14b (10mg,39.81umol) was dissolved in a solution of tetrahydrofuran (0.3 mL)/water (0.1mL), and lithium hydroxide monohydrate (5.01mg,119.42umol) was added thereto, followed by stirring at 16 ℃ for 5 hours. 4M hydrochloric acid was added to adjust pH to 2-3, extraction was performed with ethyl acetate (2X 10mL), and the solvent was spin-dried to give crude compound 14 c.

LCMS(ESI)m/z:237.8[M+1] ⁺

Step four

Compound 14c (10mg,42.16umol) was dissolved in N, N dimethylformamide (0.5mL), and compound 1h (16.33mg,42.16umol, TFA), HATU (24.05mg,63.24umol), N-diisopropylethylamine (16.35mg,126.48umol,22.03uL) was added and stirred at 16 ℃ for 3 hours. The reaction solution was directly spin-dried to obtain a crude product, which was then separated by preparative chromatography (column: Boston Green ODS 150X 30mm5 μm; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 23% -53%, 8min) to obtain the trifluoroacetate of example 14. The trifluoroacetate salt of example 14 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 14.

LCMS(ESI)m/z:493.1[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δppm 8.43(d,J＝4.02Hz,1H),8.19(d,J＝3.04Hz,2H),7.89(d,J＝9.20Hz,1H),7.66(d,J＝4.02Hz,1H),7.62(d,J＝3.04Hz,1H),7.60(d,J＝2.76Hz,1H),5.06(s,2H),3.99(s,2H),3.91(s,2H),3.83(s,4H),2.42(s,3H),34(s,3H).

Examples 15 and 16

Step one

Compound 1c (6.5g,31.68mmol) was added to methanol (50mL), sodium borohydride (3.60g,95.03mmol) was added at 0 deg.C, and stirred at 0 deg.C for 1 hr. The reaction mixture was added with water (100mL), extracted with ethyl acetate (100mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give compound 15 a.

¹H NMR(400MHz,DMSO-d6)δ8.68(d,J＝4.5Hz,1H),8.42(d,J＝2.3Hz,1H),7.98-7.95(m,1H),7.91(d,J＝4.5Hz,1H),7.89-7.84(m,1H),5.41(d,J＝4.5Hz,1H),4.90-4.79(m,1H),1.38(d,J＝6.5Hz,3H).

Step two

15a (6.5g) was separated by SFC (column: Phenomenex-Amylose-1(250 mm. times.30 mm,5 μm); mobile phase: [ 0.1% aqueous ammonia ethanol ]; B%: 25% -25%, min). 15b1 (retention time: 1.882min) and 15b2 (retention time: 2.010min) were obtained.

Step three

15b1(882.61mg,4.26mmol), N, N-disuccinimidyl carbonate (1.49g,5.81mmol) and 4-N, N-dimethylaminopyridine (236.54mg,1.94mmol), triethylamine (391.85mg,3.87mmol,538.99uL) were added to DMF (1mL) and the mixture was stirred at 60 ℃ for 0.5hr to give an intermediate product. A mixed solution of triethylamine (391.85mg,3.87mmol,538.99uL), 4-N, N-dimethylaminopyridine (236.54mg,1.94mmol) and compound 1h (1.5g,3.87mmol, trifluoroacetate) in DMF (1mL) was added at 25 ℃ and reacted for 0.5hr at 25 ℃. The reaction was directly sent to a preparative column (column: Welch Xitinate C18150 x 25mm x 5 um; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 24% -44%, 12min) and purified to give the trifluoroacetate salt of example 15. The trifluoroacetate salt of example 15 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 15.

LCMS(ESI)m/z:507.0[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ＝8.52(d,J＝4.4Hz,1H),8.48(s,1H),8.07-7.93(m,2H),7.72(d,J＝4.2Hz,1H),6.23(br s,1H),5.92(q,J＝6.8Hz,1H),4.01-3.60(m,8H),2.40(s,3H),2.34(s,3H),1.66(d,J＝6.8Hz,3H).

The trifluoroacetate salt of example 16 was obtained in the same manner as in 15b 2. The trifluoroacetate salt of example 16 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 16.

LCMS(ESI)m/z:507.2[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ＝8.53(d,J＝4.4Hz,1H),8.48(s,1H),8.07-7.95(m,2H),7.72(d,J＝4.2Hz,1H),6.23(br s,1H),5.91(q,J＝6.8Hz,1H),3.98-3.65(m,8H),2.40(s,3H),2.34(s,3H),1.66(d,J＝6.8Hz,3H).

Examples 17 and 18

Step one

2, 4-dichloro-6-methylpyrimidine (2g,12.27mmol) and 3-cyclopropyl-5-amino-1H-pyrazole (1.66g,13.50 mmol) were dissolved in dimethylsulfoxide (30mL), N-diisopropylethylamine (2.38g,18.40mmol,3.21mL) was added thereto, and the mixture was stirred at 50 ℃ for 4 hours, then the reaction mixture was added to 500mL of water, stirred for 30 minutes, and then a solid was precipitated and filtered to obtain Compound 17 a.

LCMS(ESI)m/z:250.3[M+1] ⁺

¹H NMR(400MHz,DMSO-d6)δppm 12.15(s,1H),10.14(s,1H),7.55-6.85(m,1H),6.76(s,1H),6.22-5.49(m,1H),2.67(d,J＝1.76Hz,1H),2.26(s,3H),1.97-1.79(m,1H),1.00-0.83(m,2H),0.77-0.60(m,2H)

Step two

Compound 17a (825mg,3.30mmol) and N-Boc piperazine (923.05mg,4.96mmol) were dissolved in dimethyl sulfoxide (15mL), N-diisopropylethylamine (1.28g,9.91mmol,1.73mL) was added, and the mixture was stirred at 140 ℃ for 5 hours. The reaction mixture was poured into 250ml of water, and a solid precipitated, followed by stirring for 30 minutes and filtration to obtain Compound 17 b. .

LCMS(ESI)m/z:400.2[M+1] ⁺

¹H NMR(400MHz,DMSO-d6)δppm 11.91(s,1H),9.26(s,1H),6.30-5.92(m,2H),3.72-3.62(m,4H),3.38(s,4H),2.12(s,3H),1.95-1.78(m,1H),1.46-1.42(m,9H),0.99-0.81(m,2H),0.76-0.59(m,2H).

Step three

To compound 17b (1.3g,3.25mmol) was added a mixed solution of trifluoroacetic acid (7.42g,65.08mmol,4.82 mL)/dichloromethane (5mL), and the mixture was stirred at 16 ℃ for 8 hours. The solvent was spun dry to give compound 17c (3g, crude, trifluoroacetate).

Step four

15b1(50mg,241.31umol) was dissolved in N, N dimethylformamide (1mL), N-disuccinimidyl carbonate (84.29mg,329.06umol) was added thereto, and the mixture was stirred at 60 ℃ for 30 minutes, and a solution of compound 17c (181.37mg,219.37umol, trifluoroacetate), triethylamine (22.20mg,219.37umol,30.53uL) and 4-N, N-dimethylaminopyridine (13.40mg,109.69umol) in N, N-dimethylformamide (1mL) was added thereto at 25 ℃ and stirred at 25 ℃ for 30 minutes. LCMS showed product formation. The reaction mixture was directly subjected to preparative column chromatography (column: Boston Green ODS 150: 30 mm. times.5. mu.m; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 25% -55%, 10min) to give the trifluoroacetate salt of example 17. The trifluoroacetate salt of example 17 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 17.

LCMS(ESI)m/z:533.1[M+1] ⁺

¹H NMR(400MHz,MeOH-d4)δppm 8.51(d,J＝4.60Hz,1H),8.46(d,J＝1.52Hz,1H),8.02-7.92(m,2H),7.70(d,J＝4.02Hz,1H),6.20(s,1H),5.90(q,J＝6.64Hz,1H),3.97-3.50(m,10H),2.38(s,3H),1.97-1.88(m,1H),1.64(d,J＝6.64Hz,3H),1.07-0.97(m,2H),0.81-0.70(m,2H).

Step five

Compound 17c (1.00g,1.21mmol, TFA) was dissolved in dichloromethane (1mL) at 0 deg.C, N-diisopropylethylamine (470.04mg,3.64mmol,633.48uL) was added and stirred for 10 minutes to prepare solution 1, while Compound 1e (200mg,969.84umol) was dissolved in dichloromethane (1mL), triphosgene (179.87mg,606.15umol), N-diisopropylethylamine (470.04mg,3.64mmol,633.48uL) was added and stirred for 10 minutes to prepare solution 2, and then solution 2 was added to solution 1 at 0 deg.C and stirred for 10 minutes. The reaction mixture was quenched by adding 0.5ml of water, the reaction mixture was spin-dried, dissolved in methanol, filtered to remove insoluble materials, the filtrate was spin-dried to give a crude product, and the crude product was separated by preparative HPLC (column: YMC-Triart Prep C18150: 40 mm. multidot.7 um; mobile phase: [ water (0.1% trifluoroacetic acid) -acetonitrile ]; B%: 25% -45%, 10min) to give the trifluoroacetate of example 18. The trifluoroacetate salt of example 18 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 18.

LCMS(ESI)m/z:532.3[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δppm 8.49(d,J＝4.52Hz,1H),7.94-7.87(m,2H),8.41(s,1H),7.68(d,J＝4.28Hz,1H),6.26(s,1H),5.01(q,J＝7.02Hz,1H),3.91-3.81(m,4H),3.69-3.60(m,4H),2.38(s,3H),1.97-1.90(m,1H),1.54(d,J＝7.02Hz,3H),1.05-0.96(m,2H),0.77-0.71(m,2H).

Example 19

Step one

To a solution of compound 19a (1.9g,8.88mmol), ethyl bromoacetate (14.08g,84.32mmol,9.33mL) in DMF (20mL) was added cesium carbonate (7.23g,22.19mmol), and the mixture was stirred at 110 ℃ for 20 hours. LCMS indicated the starting material had reacted to completion and product was formed. The reaction solution is filtered by diatomite to obtain filtrate, and then the filtrate is decompressed and concentrated by an oil pump to obtain a crude product. The crude product was isolated by flash column chromatography on silica gel (PE: EA ═ 3:1, Rf ═ 0.61) to afford compound 19 b.

LCMS(ESI)m/z:299.7[M+1] ⁺,301.7[M+3] ⁺

Step two

To a solution of compound 19b (2g,6.66mmol) in THF (10mL)/MeOH (10mL)/H2O (10mL) was added lithium hydroxide monohydrate (2.80g,66.63mmol) and stirred at 20 ℃ for 16H. The reaction mixture was concentrated to remove tetrahydrofuran and methanol, water (20mL) was added, extraction was performed with ethyl acetate (20mL × 2) to remove impurities, the pH of the aqueous phase was adjusted to 3 with 4N HCl, extraction was performed with ethyl acetate (20mL × 2), drying was performed with anhydrous sodium sulfate, and concentration was performed under reduced pressure to obtain compound 19 c.

LCMS(ESI)m/z:271.8[M+1] ⁺,273.8[M+3] ⁺

¹H NMR(400MHz,DMSO-d6)δ12.68(br s,1H),6.73-6.93(m,2H),6.50(d,J＝8.53Hz,1H),4.14-4.25(m,2H),4.06(s,2H),3.37-3.43(m,2H).

Step three

To a solution of compound 19c (0.1g,367.52umol), compound 1h (341.67mg,882.05umol, trifluoroacetate) in DMF (3mL) was added HATU (209.61mg,551.28umol), N, N-diisopropylethylamine (142.50mg,1.10mmol,192.05 uL). Stirred at 20 ℃ for 16 hours. To the reaction mixture was added water (15mL), and ethyl acetate (10mL × 2) was added for extraction, and the organic phases were combined and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. The crude product was isolated on a thin layer chromatography plate (PE: EA ═ 0:1, Rf ═ 0.44) to afford compound 19 d.

LCMS(ESI)m/z:527.0[M+1] ⁺,529.0[M+1] ⁺

Step four

To a solution of compound 19d (100mg,189.60umol), 4-fluoro-1 hydro-pyrazole (16.32mg,189.60umol) in DMF (4mL) was added cuprous iodide (3.61mg,18.96umol), cesium carbonate (123.55mg,379.21umol), (1S,2S) -N1, N2-dimethylcyclohexanediamine (5.39mg,37.92 umol). Stirring is carried out for 16 hours at 110 ℃ under the protection of nitrogen. The reaction solution was filtered to collect the filtrate. The filtrate was sent to a preparative chromatography column (column: Gemini 150 x 25mm 5 μm; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 17% -47%, 11.5min) to separate the white solid product, the trifluoroacetate salt of example 19. The trifluoroacetate salt of example 19 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 19.

LCMS(ESI)m/z:533.1[M+1] ⁺

¹H NMR(400MHz,DMSO-d6)δ12.32(s,1H),11.01(s,1H),8.46(d,J＝4.52Hz,1H),7.68(d,J＝4.27Hz,1H),7.06-7.09(m,1H),7.10(s,1H),6.65(d,J＝8.78Hz,1H),4.36(s,2H),4.21-4.29(m,2H),3.89(br s,2H),3.79(br s,2H),3.70(br s,2H),3.62-3.66(m,2H),3.42(br d,J＝4.27Hz,2H),2.33(s,3H),2.25(s,3H).

Examples 20, 21 and 22

Step one

Compound 20a (10g,50.19mmol) was dissolved in tetrahydrofuran (50mL), lithium bis (trimethylsilyl) amide (8.40g,50.19mmol,1M) was added dropwise to the reaction mixture at-78 ℃ under stirring for 0.5 hour, and then N-phenylbis (trifluoromethanesulfonyl) imide (17.93g,50.19mmol) was dissolved in THF (50mL) and added dropwise to the reaction mixture. The reaction solution was warmed to 0 ℃ and stirred for reaction for 3 hours. And adding 3mL of saturated ammonium chloride aqueous solution into the reaction solution to quench the reaction, then directly adding anhydrous sodium sulfate, drying, filtering, collecting the filtrate, and evaporating to dryness by rotary evaporation to obtain a crude product. The crude product was purified by silica gel column (PE/EA ═ 10/1, Rf ═ 0.8) to give a mixture of compounds 20b1 and 20b2 in a molar ratio of about 3: 1.

¹H NMR(400MHz,CHLOROFORM-d)δ7.69(s,1H),5.93(s,0.35H),4.05～4.03m,0.7H),3.57～3.43(m,2.7H),2.45～2.42(m,2H),1.96～1.89(m,2.7H),1.49(s,9H),1.47(s,3H).

Step two

A mixture of compound 20b1(6g,18.11mmol), compound 20b2(2g,6.04mmol), bis pinacol boronate (7.36g,28.98mmol), Pd (dppf) Cl₂(1.06g,1.45mmol) and potassium acetate (7.11g,72.44mmol) were added together to dioxane (160mL) and then heated to 80 ℃ by an oil bath under nitrogen and the reaction stirred for 16 h. And filtering the reaction solution, collecting filtrate, and spin-drying to obtain a crude product. The crude product was passed through a flash column (PE/EA: 10/1, Rf 1: 0.76)&Rf2 ═ 0.72) to give a mixture of compounds 20c1 and 20c2 in a molar ratio close to 3: 1.

¹H NMR(400MHz,CHLOROFORM-d)δ7.79(m,1H),6.62(s,1H),3.96(s,2H),3.51(s,3H),2.19～2.16(m,3H),1.80～1.72(m,3H),1.45(s,13H),1.32(s,5H),1.23(s,16H).

Step three

A mixture of compound 20c1(1g,3.23mmol), compound 20c2(300.00mg,970.22umol), compound 1f (940.34mg,4.20mmol), Pd (PPh)₃) ₄(373.72mg,323.41umol) and K₂CO ₃(1.79g,12.94mmol) were added together to dioxane (12mL) and water (4mL), and the reaction was heated to 125 ℃ by a microwave synthesizer under nitrogen and stirred for 0.5 h. To the reaction solution, 5mL of water and 5mL of ethyl acetate were added for extraction, followed by liquid separation, extraction of the aqueous phase with 5mL of ethyl acetate again, and the organic phases were combined, dried over anhydrous sodium sulfate, and rotary-evaporated to dryness to obtain a crude product, which was purified by flash silica gel column (dichloromethane/methanol-10/1, Rf-0.43) to obtain a mixture of compounds 20d1 and 20d 2.

LCMS(ESI)m/z:371.3[M+1] ⁺

Step four

A mixture of compound 20d1(100mg,269.94umol), compound 20d2(100.00mg,269.94umol), ammonium formate (170.21mg,2.70mmol) and Pd/C (50mg, 10% content) were added together to ethanol (5mL), then heated to 70 ℃ under an oil bath and the reaction stirred for 4 hours. The reaction solution was directly filtered, the filtrate was collected, and the crude product was obtained by rotary evaporation under reduced pressure and purified by preparative chromatography plate (dichloromethane/methanol: 20/1, Rf: 0.4) to obtain compound 20 e.

LCMS(ESI)m/z:373.3[M+1] ⁺

Step five

Compound 20e (60mg,161.09umol) and hydrogen chloride/ethyl acetate (4M,2mL) were added in one portion to EtOAc (2mL) and the reaction was stirred at 20-30 ℃ for 16 h. The reaction solution was directly evaporated to dryness by rotary evaporation. Compound 20f (hydrochloride) was obtained and used directly in the next step.

LCMS(ESI)m/z:273.2[M+1] ⁺

Step six

Compound 20f (25mg,80.96umol) and N, N-diisopropylethylamine (31.39mg,242.88umol) were added to DCM (2mL), followed by compound 1e (16.70mg,80.96umol), N, N-diisopropylethylamine (31.39mg,242.88umol,42.31uL) and triphosgene (12.01mg,40.48umol) being added together and stirred for 10 minutes and then added to the stirred reaction solution at 0 ℃ and the reaction solution stirred for 10 minutes at 25-30 ℃. The reaction mixture was quenched with 1mL of water, extracted with 5mL of water and 5mL of dichloromethane, separated, the aqueous phase extracted with 5mL of dichloromethane, the organic phases combined, dried over anhydrous sodium sulfate, evaporated to dryness to give a crude product, which was purified by preparative separation (column: Boston Green ODS 150 x 305 u; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 33% -53%, 7min) to give the trifluoroacetate salt of example 20. The trifluoroacetate salt of example 20 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 20.

LCMS(ESI)m/z:505.3[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ8.50～8.49(m,1H),8.39(d,J＝8.4Hz,1H),7.90(d,J＝8.4Hz,2H),7.70(t,J＝3.6Hz,1H),7.56(s,1H),6.61(s,1H),5.02～4.97(m,1H),4.30～4.27(m,1H),4.05～3.97(m,1H),3.27～3.10(m,2H),2.96～2.87(m,1H),2.48(d,J＝6.8Hz,3H),2.33(d,J＝4Hz,3H),2.17(s,1H),2.04～1.91(m,2H),1.63(m,1H),1.54(d,J＝6.8Hz,3H).

Step seven

The trifluoroacetate salt from example 20(60mg,118.92umol) was subjected to SFC separation (column: DAICEL CHIRALPAK AS-H (250mm 30mm,5 um); mobile phase: [ 0.1% aqueous ammonia ethanol ]; B%: 50% -50%, min). Example 21 (retention time: 3.391min) and example 22 retention times were finally obtained: 4.092min)

Example 21:

LCMS(ESI)m/z:505.2[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ8.48(d,J＝4.4Hz,1H),8.38(s,1H),7.87～7.85(m,2H),7.68(d,J＝4Hz,1H),6.74(s,1H),6.19(s,1H),5.03～4.98(m,1H),4.23(d,J＝13.2Hz,1H),4.11(d,J＝13.2Hz,1H),3.25～3.19(m,1H),2.88～2.81(m,2H),2.33(s,3H),2.29(s,3H),2.12(s,1H),1.89～1.81(m,2H),1.61～1.60(m,1H),1.52(d,J＝7.2Hz,3H)

example 22:

LCMS(ESI)m/z:505.2[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ8.36(d,J＝4Hz,1H),8.28(d,J＝1.6Hz,1H),7.81～7.75(m,2H),7.84(s,1H),7.55(d,J＝4Hz,1H),6.62(s,1H),6.08(s,1H),4.90～4.85(m,1H),4.11(d,J＝13.2Hz,1H),4.00(d,J＝13.2Hz,1H),3.11～3.05(m,1H),2.74～2.70(m,2H),2.22(s,3H),2.17(s,3H),1.99(s,1H),1.77～1.66(m,2H),1.47(m,1H),1.39(d,J＝7.2Hz,3H)

example 23

Step one

Compound 1e (200mg,969.84umol)) And Boc₂O (222.25mg,1.02mmol) was added together to THF (4mL) and H₂O (4mL), and then the reaction was stirred at 10 ℃ for 16 hours. The reaction solution was directly rotary evaporated to dryness to give crude compound 23a, which was used directly in the next step.

LCMS(ESI)m/z:307.3[M+1] ⁺

Step two

Compound 23a (250mg,816.10umol) was dissolved in THF (5mL), then sodium hydrogen (65.28mg,1.63mmol, 60%) was added to the reaction solution, stirred for ten minutes, iodomethane (231.67mg,1.63mmol) was added to the stirred reaction solution, and finally the reaction solution was stirred at 20 ℃ for 16 hours. Adding 5mL of water into the reaction solution to quench the reaction, then adding 20mL of ethyl acetate for extraction, separating the solution, extracting the aqueous phase with 20mL of ethyl acetate again, combining the organic phases, drying the organic phases with anhydrous sodium sulfate, and carrying out rotary evaporation and evaporation to obtain the compound 23 b.

LCMS(ESI)m/z:320.9[M+1] ⁺

Step three

Compound 23b (200mg,624.30umol) was dissolved in ethyl acetate (5mL), and then hydrogen chloride/ethyl acetate (4M,4.00mL) was added to the reaction solution, followed by stirring at 20 ℃ for 16 hours. The reaction solution was directly filtered, and the filter cake was compound 23 c.

LCMS(ESI)m/z:220.9[M+1] ⁺

Step four

Compound 1h (140mg,453.35umol, HCl) and N, N-diisopropylethylamine (175.77mg,1.36mmol) were added to dichloromethane (5mL), followed by compound 23c (99.85mg,453.35umol), N, N-diisopropylethylamine (175.77mg,1.36mmol,236.89uL) and triphosgene (67.27mg,226.68umol) being added together and stirred for 10 minutes and then added to the stirred reaction solution at 0 ℃ and the reaction solution stirred for 10 minutes at 15-20 ℃. Directly rotary-evaporating the reaction solution to dryness to obtain a crude product. The crude product was sent to preparative separation (column: Boston Green ODS 150 x 30mm x 5 um; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 30% -60%, 9min) to give the trifluoroacetic acid salt of example 23. The trifluoroacetate salt of example 23 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 23.

LCMS(ESI)m/z:519.1[M+1] ⁺

¹H NMR(400MHz,METHANOL-d ₄)δ8.51(br d,J＝3.8Hz,1H),8.44(br s,1H),7.95(br s,2H),7.71(br s,1H),6.37(s,1H),6.24(s,1H),5.83(s,1H),5.33(br d,J＝6.8Hz,1H),3.70(br s,4H),3.55(br s,4H),2.79(s,3H),2.39(s,3H),2.34(s,3H),1.67(br d,J＝6.8Hz,3H)

Examples 24 and 25

Step one

Potassium permanganate (45.60g,288.54mmol) was added to a mixed solution of compound 24a (7g,48.09mmol) in water (60mL) and pyridine (60mL), and the mixture was stirred at 100 ℃ for 3 hours. The reaction solution is directly filtered, washed by 100mL of methanol, and the filtrate is decompressed and concentrated to obtain the compound 24 b.

¹H NMR(400MHz,DMSO-d ₆)δ8.60(s,1H),8.02(dd,J＝1.64,9.16Hz,1H).

Step two

Compound 24b (4g,22.79mmol), N, O-dimethylhydroxylamine hydrochloride (1.39g,22.79mmol) in DMF (100mL) was added to HATU (13.00g,34.18mmol), N, N-diisopropylethylamine (5.89g,45.57mmol,7.94mL) and stirred at 30 ℃ for 2 h. The reaction mixture was added with 100mL of water, and ethyl acetate (100mL × 2) was added for extraction, and the organic phases were combined and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. The crude product was isolated (PE: EA ═ 4:3, Rf ═ 0.42) to give compound 24 c.

LCMS(ESI)m/z:218.6[M+1] ⁺

¹H NMR(400MHz,CHLOROFORM-d)δ8.56(d,J＝1.76Hz,1H),7.83(dd,J＝1.88,8.42Hz,1H),3.52-3.57(m,3H),3.30-3.39(m,3H).

Step three

Methylmagnesium bromide (3M,5.49mL) was added dropwise to a solution of compound 24c (3g,13.72mmol) in THF (30mL) at 0 deg.C, and stirred for 2 hours at 25 deg.C. To the reaction mixture was added a saturated ammonium chloride solution (50mL), followed by extraction with ethyl acetate (50mL × 2), and the organic phases were combined and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. The crude product was isolated on a flash silica gel column (PE: EA ═ 3:1, Rf ═ 0.43) to afford compound 24 d.

LCMS(ESI)m/z:173.8[M+1] ⁺

¹H NMR(400MHz,CHLOROFORM-d)δ8.75(d,J＝1.52Hz,1H),7.99(dd,J＝1.64,8.16Hz,1H),2.65(s,3H).

Step four

To a solution of compound 24d (1.3g,7.49mmol), 1H-pyrazole (509.88mg,7.49mmol) in DMF (20mL) was added K₂CO ₃(3.11g,22.47mmol), and stirred at 100 ℃ for 16 hours. The reaction solution is filtered by diatomite, and the filtrate is decompressed and concentrated by an oil pump to obtain a crude product. The crude product was isolated on preparative chromatography plates (PE: EA ═ 3:1, Rf ═ 0.38) to give compound 24 e.

LCMS(ESI)m/z:205.8[M+1] ⁺

¹H NMR(400MHz,CHLOROFORM-d)δ8.84(s,1H),8.46(d,J＝2.76Hz,1H),8.15(dd,J＝1.76,11.54Hz,1H),7.89(d,J＝1.00Hz,1H),6.52-6.61(m,1H),2.66(s,3H).

Step five

To a solution of compound 24e (0.60g,2.92mmol) in methanol (10mL) was added ammonium acetate (2.25g,29.24mmol), and after stirring at 65 ℃ for 1 hour, NaBH was added₃CN (551.26mg,8.77mmol, stirring at 65 ℃ for 3 hours, directly concentrating the reaction solution to obtain a crude product, separating the crude product by preparative chromatography plate (DCM: MeOH: 10:1, Rf: 0.20) to obtain a product 24f, and further separating by SFC (column: DAICEL CHIRALPAK AD-H (250mm 30mm,5 μm); mobile phase: [ 0.1% ammonia water methanol: ] to obtain a crude product](ii) a 35% -35% of B%, min) to obtain 24g of 1 (retention time: 4.177min) and 24g2 (retention time: 4.980 min).

24g1:

LCMS(ESI)m/z:206.8[M+1] ⁺

¹H NMR(400MHz,CHLOROFORM-d)δ8.28(s,2H),7.83(d,J＝1.00Hz,1H),7.70(dd,J＝1.63,11.92Hz, 1H),6.46-6.55(m,1H),4.28(q,J＝6.70Hz,1H),1.43(d,J＝6.54Hz,3H).

24g2:

LCMS(ESI)m/z:206.8[M+1] ⁺

¹H NMR(400MHz,CHLOROFORM-d)δ8.28(s,2H),7.82(d,J＝1.26Hz,1H),7.69(dd,J＝1.64,11.92Hz,1H),6.47-6.51(m,1H),4.27(q,J＝6.62Hz,1H),1.42(d,J＝6.54Hz,3H).

Step six

To a solution of compound 24g1(59.63mg,289.14umol) at 0 ℃ in DCM (2mL) was added N, N-diisopropylamine (140.13mg,1.08mmol,188.86uL), triphosgene (53.63mg,180.71umol), and stirred at 0 ℃ for 10 minutes, and the reaction solution was added dropwise to a single vial containing compound 1h (140mg,361.42umol, trifluoroacetate), N, N-diisopropylamine (140.13mg,1.08mmol,188.86uL), and DCM (2mL), and stirring was continued at 0 ℃ for 10 minutes. 3mL of water was added to the reaction mixture, which was extracted with dichloromethane (3 mL. times.3), and the combined organic phases were concentrated under reduced pressure to give a crude product. The crude product was sent to preparative chromatography (column: Boston Green ODS 150 x 30mm5 μm; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 21% -41%, 7min) to give the trifluoroacetate salt of example 24. The trifluoroacetate salt of example 24 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 24.

LCMS(ESI)m/z:506.2[M+1] ⁺

¹H NMR(400MHz,DMSO-d ₆) δ 12.39(br s,1H),11.72(br s,1H),11.05(br s,1H),8.31 to 8.43(m,1H),7.90 to 7.99(m,1H),7.80 to 7.87(m,1H),7.09(d, J ═ 7.54Hz,1H),6.58(t, J ═ 2.02Hz,1H),6.09 to 6.45(m,2H),4.98(q, J ═ 7.10Hz,1H),3.78(br s,4H),3.54(br s,4H),2.33(s,3H),2.25(s,3H),1.46(d, J ═ 7.03Hz,3H), the trifluoroacetate of example 25 was prepared in the same manner as compound 24g 2. The trifluoroacetate salt of example 25 is added to sodium bicarbonate solution, extracted with ethyl acetate and the organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure to give example 25.

LCMS(ESI)m/z:506.2[M+1] ⁺

¹H NMR(400MHz,DMSO-d ₆)δ12.09-12.66(m,1H),11.45-12.01(m,1H),11.04(br s,1H),8.30-8.43(m,1H),7.95(dd,J＝1.52,11.80Hz,1H),7.83(d,J＝1.52Hz,1H),7.08(d,J＝7.54Hz,1H),6.58(t,J＝2.14Hz,1H),6.37(br s,1H),6.18(br s,1H),4.98(q,J＝7.04Hz,1H),3.78(br s,5H),3.53(br s,3H),2.32(s,3H),2.24(s,3H),1.46(d,J＝7.04Hz,3H).

Examples 26 and 27

Step one

Compound 1f (3.56g,15.90mmol) was dissolved in 1-methylpyrrolidone (15mL), ethyl 3-carboxylate piperidine (5g,31.80mmol), N-diisopropylethylamine (6.17g,47.71mmol,8.31mL) were added, and stirring was carried out at 90 ℃ for 16 hours. The reaction mixture was extracted with ethyl acetate (40mL × 3) and the organic phases were combined, washed with water (100mL × 5), saturated sodium chloride solution (100mL × 1), dried over anhydrous sodium sulfate, filtered and the solution was spin-dried to give the crude product. The crude product was purified by flash silica gel column (PE: EA ═ 1:1) to afford compound 26 a.

LCMS(ESI)m/z:345.2[M+1] ⁺

¹H NMR(400MHz,DMSO-d6)δppm 9.23(s,1H),11.85(s,1H),6.15(s,1H),4.67(d,J＝10.79Hz,1H),4.43(d,J＝12.80Hz,1H),4.13-4.08(m,2H),3.17(d,J＝5.26Hz,1H),3.06(t,J＝11.54Hz,1H),2.99-2.89(m,1H),2.47-2.41(m,1H),2.19(s,3H),2.11(s,3H),2.03–1.96(m,1H),1.74-1.57(m,2H),1.45-1.36(m,1H),1.19(t,J＝7.16Hz,4H).

Step two

Compound 26a (100mg,290.35umol) was dissolved in a tetrahydrofuran (1 mL)/water (0.3mL) solution, and lithium hydroxide monohydrate (36.55mg,871.05umol) was added thereto, followed by stirring at 16 ℃ for 2 hours. The reaction solution was adjusted to pH 2-3 with 4N hydrochloric acid, extracted with ethyl acetate (10mL × 2), and the solvent was dried to give compound 26 b. .

LCMS(ESI)m/z:316.9[M+1] ⁺

Step three

Compound 26b (90mg,284.49umol) was dissolved in N, N dimethylformamide (1mL), and compound 1e (58.67mg,284.49umol), HATU (162.26mg,426.73umol), N-diisopropylethylamine (110.30mg,853.46umol,148.66uL) was added thereto, followed by stirring at 16 ℃ for 3 hours, and the solvent was spin-dried to obtain the crude product. The crude product was separated and purified by preparative chromatography (column: Xtimate C18150 × 25mm × 5 um; mobile phase: [ water (0.1% trifluoroacetic acid) -acetonitrile ]; B%: 30% -40%, 11min) and the product was resolved by SFC (column: DAICEL CHIRALCEL OJ-H (250mm × 30mm,5 um); mobile phase: [ 0.1% aqueous ammonia ethanol ]; B%: 30% -30%, min) to give example 26 (retention time: 2.947min), example 27 (retention time: 3.504 min).

Example 26:

LCMS(ESI)m/z:505.7[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δppm 8.44(dd,J＝4.52,0.80Hz,1H),8.30(d,J＝2.00Hz,1H),7.84-7.79(m,1H),7.78-7.73(m,1H),7.66(d,J＝4.28Hz,1H),6.11(s,1H),6.02(s,1H),5.07(q,J＝6.80Hz,1H),4.29(dd,J＝13.60,3.20Hz,1H),4.21-4.11(m,1H),3.57-3.51(m,2H),3.40-3.33(m,1H),2.58-2.45(m,1H),2.17(d,J＝9.06Hz,6H),2.00–1.89(m,2H),1.71-1.63(m,1H),1.45(d,J＝7.04Hz,3H).

example 27:

LCMS(ESI)m/z:505.6[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δppm 8.46(d,J＝4.02Hz,1H),8.35(s,1H),7.94-781(m,2H),7.67(d,J＝4.28Hz,1H),5.05(q,J＝7.04Hz,1H),4.38(d,J＝12.00Hz,1H),4.21(d,J＝13.80Hz,1H)3.54-3.49(m,2H),3.35(s,1H),2.65-2.54(m,1H),2.35-2.27(m,6H),2.08-1.98(m,1H),1.87-1.78(m,2H),1.70-1.58(m,1H),1.50(d,J＝7.20Hz,3H).

examples 28 and 29

Step one

Compound 15b1(335.49mg,1.62mmol), N, N-disuccinimidyl carbonate (622.15mg,2.43mmol) and 4-N, N-dimethylaminopyridine (98.90mg,809.56umol) together with triethylamine (163.84mg,1.62mmol,225.36uL) were added to DMF (5mL), and then the reaction was stirred at 60 ℃ for 1 hour, then a solution of compound 20f (500mg,1.62mmol, HCl) and triethylamine (163.84mg,1.62mmol) in DMF (5mL) was added to the reaction solution at 25 ℃ and finally the reaction solution was stirred at 25 ℃ for 0.5 hour. The reaction solution is directly concentrated under reduced pressure to obtain a crude product. Purifying with preparative chromatographic column (chromatographic column: Phenomenex Gemini-NX 150: 30 mM: 5 um; mobile phase: [ water (0.04% ammonia water +10mM ammonium bicarbonate) -acetonitrile ]; B%: 39% -69%, 8 min). And then sent to preparative chromatography column (column: Boston Green ODS 150: 30 mm: 5 um; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile ]; B%: 25% -55%, 7min) to obtain Compound 28 a.

LCMS(ESI)m/z:506.2[M+1] ⁺

Step two

28a (130mg,257.15umol) was sent to SFC for separation. SFC conditions were (column: DAICEL CHIRALPAK AD (250 mm. about.30 mm,10um), mobile phase: [ 0.1% NH3H2O, IPA ]; B%: 60% -60%, min). Finally, example 28 (retention time: 1.499min) and example 29 (retention time: 2.252min) were obtained.

Example 28

LCMS(ESI)m/z:506.1[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ8.46-8.21(m,2H),7.90-7.71(m,2H),7.57(br s,1H),6.73-5.99(m,1H),5.73(q,J＝6.5Hz,1H),5.19-5.00(m,1H),4.24-4.02(m,2H),2.90-2.55(m,2H),2.21(br s,3H),2.16(s,3H),1.99(br d,J＝11.8Hz,1H),1.75(br s,2H),1.55-1.37(m,5H).

Example 29

LCMS(ESI)m/z:506.6[M+1] ⁺

¹H NMR(400MHz,METHANOL-d4)δ＝8.49(d,J＝4.4Hz,1H),8.43(br s,1H),7.97-7.89(m,2H),7.68(d,J＝4.3Hz,1H),6.78-6.16(m,1H),5.85(br s,1H),5.32-5.19(m,1H),4.36-4.29(m,2H),3.04-2.72(m,2H),2.30-2.25(m,1H),2.28(s,2H),2.05-2.03(m,4H),1.84(br d,J＝11.0Hz,2H),1.61-1.53(m,5H).

Biological test data:

experimental example 1: in vitro enzymatic Activity assay for Compounds of the invention

Purpose of experiment

By Z' -LYTE^TMKinase assay to detect enzyme activity as IC of compound₅₀The values are used as indicators to evaluate the inhibitory effect of compounds on RET and RET (V804M) kinase.

Experimental methods

Testing of RET and RET (V804M) kinase compounds were diluted 3-fold at 10 concentrations from 3 μ M to 0.152 nM; the content of DMSO in the assay reaction was 1%.

Reagent:

basic reaction buffer, 20mM hydroxyethylpiperazine ethanethiosulfonic acid (Hepes) (pH 7.5) buffer, 10mM MgCl₂Ethylene glycol bisaminoethylether tetraacetic acid (EGTA) at 1mM, polyoxyethylene dodecanol ether (Brij35) at 0.02% by weight, bovine serum albumin () at 0.02mg/ml, Na at 0.1mM₃VO ₄2mM Dithiothreitol (DTT), 1% DMSO.

A compound:

the test compound was dissolved in 100% DMSO and diluted to 10mM for use. Solution dilution was performed using an Integra Viaflo Assist. Reaction process of general enzyme:

and (3) testing conditions are as follows: the concentration of RET enzyme is 3 mu M, the concentration of peptide substrate CHKtide is 1000 mu M, and the concentration of ATP is 20 mu M; the concentration of RET (V804M) enzyme was 80. mu.M, the concentration of substrate peptide was 1000. mu.M, and the concentration of ATP was 30. mu.M.

The reaction process is as follows: kinase/polypeptide solutions were prepared according to the test conditions. The compound solutions of different concentrations were added and incubated for 20 minutes at room temperature, the corresponding concentration of 33P-ATP was added and the reaction was incubated for 120 minutes at room temperature. Radioactivity was detected by the filter-binding method.

Reaction detection:

the reaction was stopped by adding 0.5% phosphoric acid to the reaction mixture, and the Envision apparatus read the plate.

Data analysis

Converting the data into phosphorylation rate and inhibition rate, and obtaining compound IC by parameter curve fitting (GraphPad Software)₅₀And (4) data.

The results are shown in Table 1:

table 1 example 1 kinase activity IC₅₀Test results

	RET enzyme IC 50 (nM)	RET V804M IC ₅₀(nM)
Hydrochloride salt of example 1	1.1	7.86
Example 2	293	609
Example 3	62.1	204
Trifluoroacetic acid salt of example 4	0.5	2.58
Example 6	60.7	69.6
Example 7	4.2	11.7
Example 8	50.4	134
Example 9	201	250
Example 10	23.9	31.7
Example 11	4.76	11.6
Example 12	68.2	83.3
Trifluoroacetic acid salt of example 13	6.73	9.16
Trifluoroacetic acid salt of example 14	4.57	8.24
Trifluoroacetic acid salt of example 15	4.00	9.00
Trifluoroacetic acid salt of example 16	7.3	11.0
Trifluoroacetic acid salt of example 17	4.3	2.74
Trifluoroacetic acid salt of example 18	1.06	2.36

Trifluoroacetic acid salt of example 19	44.9	35.6
Trifluoroacetic acid salt of example 20	4.31	4.19
Example 21	96.4	91.4
Example 22	0.9	1.62
Trifluoroacetic acid salt of example 23	1.35	12.8
Trifluoroacetic acid salt of example 24	22.6	24.7
Trifluoroacetic acid salt of example 25	5.67	14.4
Example 26	N/A	N/A
Example 27	N/A	N/A
Example 28	231	131
Example 29	2.40	4.77

N/A represents not detected

And (4) experimental conclusion: the compound has excellent inhibitor activity on RET and mutant RET V804M thereof, and has excellent treatment effect on patients with RET abnormal tumors.

Claims

A compound represented by the formula (III), an isomer thereof or a pharmaceutically acceptable salt thereof,

wherein the content of the first and second substances,

a ring is selected from
The above-mentioned
Optionally substituted by 1,2 or 3R_gSubstitution;

R ₁selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl radical, C_1-3Alkoxy and C_3-6Cycloalkyl radical, said C_1-3Alkyl radical, C_1-3Alkoxy and C_3-6Cycloalkyl is optionally substituted by 1,2 or 3R_aSubstitution;

R ₂selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl and C_1-3Alkoxy radical, said C_1-3Alkyl and C_1-3Alkoxy is optionally substituted by 1,2 or 3R_bSubstitution;

R ₄selected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-5Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and a 5-6 membered heteroaromatic ring, said C_1- ₅Alkyl radical, C_1-5Alkoxy radical, C_1-5Alkylamino and 5-6 membered heteroaromatic rings optionally substituted with 1,2 or 3R_dSubstitution;

R _aand R_bEach independently selected from F, Cl, Br, I, OH and NH₂；

R _dSelected from H, F, Cl, Br, I, OH, NH₂、CN、C _1-3Alkyl radical, C_1-3Alkoxy and C_1-4An alkylamino group;

T ₁、T ₂、T ₃and T₅Each independently selected from CH and N;

T ₄selected from the group consisting of CR₅And N;

L ₂selected from NH and O;

L ₃is selected from-CH (R)₆)-、-CH(R ₆)CH ₂-、-CHCH ₂CH ₂-、-CH(R ₆)-O-、-CHCH ₂-O-、-CH ₂-N(R ₆)-、-CH ₂CH ₂-N(R ₆)-；

R ₅Is selected from H;

R ₆is selected from H and CH₃；

Or R₅、R ₆Are connected together to form a structural unit
Is selected from

R _gSelected from H, F, Cl, Br, I, OH, NH₂And CN;

the 5-to 6-membered heteroaryl group comprises 1,2,3 or 4 heteroatoms or groups of heteroatoms independently selected from-NH-, -O-, -S-and N, respectively.
A compound, isomer thereof or pharmaceutically acceptable salt thereof according to claim 1, wherein R₁Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂CH ₃、
The CH₃、CH ₂CH ₃、
Optionally substituted by 1,2 or 3R_aAnd (4) substitution.
A compound, isomer thereof or pharmaceutically acceptable salt thereof according to claim 2, wherein R₁Is selected from CH₃And
a compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R₂Selected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃、CH ₂CH ₃And
the CH₃、CH ₂CH ₃And
optionally substituted by 1,2 or 3R_bAnd (4) substitution.
A compound, isomer thereof or pharmaceutically acceptable salt thereof according to claim 4, wherein R₂Is selected from CH₃。
Any of claims 1 to 3The compound, an isomer thereof, or a pharmaceutically acceptable salt thereof, wherein R_dSelected from H, F, Cl, Br, I, OH, NH₂、CN、CH ₃And
a compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R₄Selected from: H. f, Cl, Br, I, OH, NH₂、CN、CH ₃Pyrazolyl, isoxazolyl, imidazolyl, triazolyl, oxazolyl,
The CH₃Pyrazolyl, isoxazolyl, imidazolyl, triazolyl, oxazolyl,
Optionally substituted by 1,2 or 3R_dAnd (4) substitution.
A compound, isomer, or pharmaceutically acceptable salt according to claim 7, wherein R₄Selected from:
the compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the structural unit
Is selected from
The compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein ring A is selected from the group consisting of
The compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the structural unit
Is selected from
The compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to claim 11, wherein the structural unit
Is selected from
The compound, an isomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the structural unit
Is selected from
The compound, isomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 10 to 13, which is selected from

Wherein R is₁、R ₂、R ₄、L ₂、L ₃、T ₁、T ₂、T ₃、T ₄And T₅The composition as defined in any one of claims 1 to 9 and 11 to 13.
A compound of the formula, an isomer thereof, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
the compound of formula, an isomer thereof, or a pharmaceutically acceptable salt thereof according to claim 15, which is selected from the group consisting of:
a pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16, an isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
Use of a compound according to any one of claims 1 to 16, an isomer thereof or a pharmaceutically acceptable salt thereof for the preparation of a RET kinase inhibitor.
Use of a composition according to claim 17 for the preparation of a RET kinase inhibitor.